MARKET

BPTH

BPTH

Bio-Path Hldgs Inc
NASDAQ
1.810
-0.020
-1.09%
After Hours: 1.850 +0.04 +2.21% 18:25 07/19 EDT
OPEN
1.820
PREV CLOSE
1.830
HIGH
1.840
LOW
1.800
VOLUME
35.08K
TURNOVER
0
52 WEEK HIGH
36.20
52 WEEK LOW
1.591
MARKET CAP
3.77M
P/E (TTM)
-0.0661
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BPTH last week (0708-0712)?
Weekly Report · 4d ago
Bio-Path Holdings Price Target Maintained With a $20.00/Share by Roth MKM
Dow Jones · 07/08 15:00
Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target
Benzinga · 07/08 14:50
Bio-Path Reports Meaningful Progress Across Key Clinical Trials In Multiple Cancer Indications
Bio-Path is developing prexigebersen as a potential treatment for obesity. The company is also developing biomarkers to incorporate into its oncology studies. Bio-Path plans to conduct first-in-human clinical studies in the global market for weight loss.
Benzinga · 07/08 11:02
BIO PATH HOLDINGS : PREXIGEBERSEN PHASE 2 CLINICAL TRIAL CURRENTLY PAUSED FOR INTERIM ANALYSIS, AMENDMENT PREPARATION, FDA REVIEW
Reuters · 07/08 11:00
Weekly Report: what happened at BPTH last week (0701-0705)?
Weekly Report · 07/08 10:35
Weekly Report: what happened at BPTH last week (0624-0628)?
Weekly Report · 07/01 10:35
Weekly Report: what happened at BPTH last week (0617-0621)?
Weekly Report · 06/24 10:40
More
About BPTH
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Webull offers Bio Path Holdings Inc stock information, including NASDAQ: BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.